A client started fezolinetant for menopausal vasomotor symptoms 3 weeks ago. The client now reports fatigue, pruritus, dark urine, and right-upper-quadrant pain. Which action should the nurse take?
1Stop fezolinetant and arrange prompt medical evaluation with hepatic laboratory testing.✓ Correct answer
2Take the next dose with food and record whether the abdominal discomfort improves.
3Continue therapy and schedule liver testing at the next routine monitoring interval.
4Skip one dose, increase oral fluids, and restart once the urine becomes lighter.
Explanation
Fatigue, pruritus, dark urine, and right-upper-quadrant pain can signal fezolinetant-associated liver injury. The label directs immediate discontinuation and medical evaluation with hepatic testing when these symptoms occur.
Quick answer Stop fezolinetant and escalate new symptoms of liver injury immediately.
Why this is correct Fezolinetant has a boxed warning for hepatotoxicity and requires baseline and scheduled liver testing. Symptom-triggered action is immediate and does not wait for the next routine monitoring point.
Easy analogy or mental picture Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.
Memory hook Drug, urgent cue, protective action, and reassessment endpoint.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.
Medication-safety reviewVerify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.